

# Screening for Dementia

## Recommendations and Rationale

### U.S. Preventive Services Task Force

This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on screening for dementia and the supporting evidence, and it updates the 1996 recommendations contained in the *Guide to Clinical Preventive Services*, second edition.<sup>1</sup> Explanations of the ratings and of the strength of overall evidence are given in Appendix A and Appendix B, respectively. The complete information on which this statement is based, including evidence tables and references, is available in the summary of the evidence<sup>2</sup> and the systematic evidence review<sup>3</sup> on this topic, which can be obtained through the USPSTF Web site ([www.preventiveservices.ahrq.gov](http://www.preventiveservices.ahrq.gov)) and through the National Guideline Clearinghouse™ ([www.guideline.gov](http://www.guideline.gov)). The summary of the evidence and the recommendation statement are also available in print by subscription to the *Guide to Clinical Preventive Services, Third Edition: Periodic Updates*. The cost of the subscription is \$60 and can be ordered through the AHRQ Publications Clearinghouse (call 1-800-358-9295 or e-mail [ahrqpubs@ahrq.gov](mailto:ahrqpubs@ahrq.gov)).

The USPSTF recommendations are independent of the U.S. government. They do not represent the views of the Agency for Healthcare Research and Quality (AHRQ), the U.S. Department of Health and Human Services, or the U.S. Public Health Service.

## Summary of Recommendation

The U.S. Preventive Services Task Force (USPSTF) concludes that the evidence is insufficient to recommend for or against routine screening for dementia in older adults. **I recommendation.**

*The USPSTF found good evidence that some screening tests have good sensitivity but only fair specificity in detecting cognitive impairment and*

*dementia. There is fair to good evidence that several drug therapies have a beneficial effect on cognitive function (equivalent to delaying the natural progression of Alzheimer's disease from 2 to 7 months), but the evidence of their beneficial effects on instrumental activities of daily living is mixed, with the benefit being small, at best. There is insufficient evidence to determine whether the benefits observed in drug trials are generalizable to patients whose disease would be detected by screening in primary care settings. The accuracy of diagnosis, the feasibility of screening and treatment in routine clinical practice, and the potential harms of screening (eg, labeling effects) are also unknown. The Task Force therefore could not determine whether the benefits of screening for dementia outweigh the harms.*

## Clinical Considerations

- The Mini-Mental Status Examination (MMSE) is the best-studied instrument for screening for cognitive impairment. When the MMSE is used to screen unselected patients, the predictive value of a positive result is only fair. The accuracy of the MMSE depends upon a person's age and educational level: using an arbitrary cut-point may potentially lead to more false-positives among older people with lower educational levels, and more false-negatives among younger people with higher educational levels. Tests that assess functional limitations rather than cognitive impairment, such as the Functional Activities Questionnaire (FAQ), can detect dementia with sensitivity and specificity comparable to that of the MMSE.
- Early recognition of cognitive impairment, in addition to helping make diagnostic and treatment decisions, allows clinicians to anticipate problems

---

Corresponding Author: Alfred O. Berg, MD, MPH, Chair, U.S. Preventive Services Task Force, c/o Center for Practice and Technology Assessment, Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD, 20850. (301) 427-1600. E-mail: [uspstf@ahrq.gov](mailto:uspstf@ahrq.gov).

the patients may have in understanding and adhering to recommended therapy. This information may also be useful to the patient's caregiver(s) and family member(s) in helping to anticipate and plan for future problems that may develop as a result of progression of cognitive impairment.

- Although current evidence does not support routine screening of patients in whom cognitive impairment is not otherwise suspected, clinicians should assess cognitive function whenever cognitive impairment or deterioration is suspected, based on direct observation, patient report, or concerns raised by family members, friends, or caretakers.

## Scientific Evidence

### Epidemiology and Clinical Consequences

Dementia is defined as an acquired syndrome of decline in memory and at least one other cognitive domain such as language, visuo-spatial, or executive function sufficient to interfere with social or occupational functioning in an alert person.<sup>4</sup> The USPSTF did not review evidence on screening individuals with “mild cognitive impairment,” a condition not associated with functional impairment but that sometimes progresses to dementia.<sup>5</sup>

Alzheimer's disease and cerebrovascular ischemia (vascular dementia) are the two most common causes of dementia. Between 60% and 70% of individuals with dementia have Alzheimer's disease; about 20% to 30% have either vascular dementia or a combination of vascular dementia and Alzheimer's disease.<sup>3</sup> Dementia causes a high burden of suffering for patients and their families. For patients, it increases dependency and complicates other medical conditions. For families, it can lead to anxiety and depression, and may increase the time needed to care for loved ones. The annual economic cost of dementia is estimated to be \$100 billion.<sup>6</sup>

Age is the strongest risk factor for dementia: 3% to 11% of people older than 65 and 25% to 47% of those older than 85 have dementia.<sup>2</sup> First degree

relatives of patients with Alzheimer's disease have a cumulative lifetime risk of 39%, approximately twice the risk of Alzheimer's disease in the general population.<sup>7</sup> Some genetic mutations have been associated with Alzheimer's disease: about 20% to 30% of the general population and 45% to 60% of people with late-onset Alzheimer's disease have the apolipoprotein E-4 (APOE-ε4) gene.<sup>8</sup> Cardiovascular risk factors such as hypertension are associated with an increased risk of both Alzheimer's disease and vascular dementia.<sup>9-11</sup>

### Accuracy and Reliability of Screening Tests

Screening tests used for dementia are either direct cognitive tests of patients or functional assessments using patients and others as informants. Most screening tests have been evaluated in studies with small sample sizes, and the populations of patients on whom screening instruments have been tested have varied greatly, making it difficult to determine the overall performance of screening tests for dementia. The best evidence is available for a cognitive test—the Mini-Mental Status Examination (MMSE)—from studies in primary care settings that used standardized diagnostic instruments (eg, the DSM-IV) as a “gold standard.” Depending upon the cutpoint used for an abnormal test, the sensitivity of MMSE for dementia ranges from 71% to 92%, and the specificity ranges from 56% to 96%.<sup>12-19</sup> The predictive value of a positive test, in a population with 10% prevalence of dementia, may range from 15% to 72%.<sup>2</sup> A drawback of MMSE is that its accuracy depends upon age, education, and ethnicity of the individual; it is most accurate for whites with at least a high school education.<sup>2</sup> Other cognitive screening tests, such as the Short Portable Mental Status Questionnaire, Clock Drawing Test, Modified MMSE, Mini-Cog, Hopkins Verbal Learning Test, and the 7-minute screen are promising, but have not been adequately evaluated in primary care settings.<sup>2</sup>

Some informant-based functional tests, such as the Functional Activities Questionnaire (FAQ), the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), and the Instrumental Activities of Daily Living (IADL) Questionnaire,

have also been tested.<sup>3,12,17</sup> The sensitivity and specificity of FAQ is reported to be 90%.<sup>12</sup> The functional test instruments offer the advantages of “everyday relevance,” acceptability by subjects, adaptability to various types of patients, administrative ease, longitudinal perspective, and cross-cultural portability. The primary limitations of these tests are that not all patients have caregivers and that some functions (eg, cognition) are not tested. Most important, few methodologically sound studies regarding the accuracy of these questionnaires in primary care settings have been completed.

Testing for genetic mutations may eventually prove useful in screening individuals at risk for Alzheimer’s disease. There are, however, limited population-based data regarding the absolute risk of dementia among individuals having a positive genetic test. Thus the potential benefits and harms of testing for an individual patient are uncertain. Finally, the ethical issues in genetic testing for dementia are unresolved.

## Effectiveness of Early Detection

The USPSTF found no direct evidence examining the effectiveness of screening for dementia in primary care settings in which the clinical outcomes of a population of patients who are screened, diagnosed, and treated are compared with outcomes in a population receiving usual care. To assess possible benefits of detecting undiagnosed dementia, the USPSTF examined trials of therapies aimed at improving the cognitive function of patients with dementia. The natural history of Alzheimer’s disease is of progressive decline in cognitive function, thus an “improvement” from an intervention means a slowing of the rate of decline.

## Pharmacological Interventions

**Cholinesterase inhibitors.** The best evidence is available for cholinesterase inhibitors, which have been studied in randomized control trials (RCTs) lasting 6–12 months in patients with mild to moderate Alzheimer’s disease. There are 2 scales of function commonly used in research on dementia: a 70-point Alzheimer’s Disease Assessment Scale for

Cognition (ADAS-Cog) and a 7-point Clinician’s Interview Based Impression of Change plus caregiver input scale (CIBIC). Four systematic reviews<sup>20–23</sup> and 5 RCTs<sup>24–28</sup> have examined the effect of cholinesterase inhibitors compared with placebo among people with mild to moderate Alzheimer’s disease. Most of these studies found a statistically significant difference favoring cholinesterase inhibitors that ranged from 2.1 to 3.4 points on ADAS-Cog. A slowing of decline by 2 to 3 ADAS-Cog points over a year is approximately equivalent to a delay in disease progression of up to 7 months in a person with mild dementia, or a delay of 2 to 5 months in a person with moderate dementia.<sup>2</sup> In addition, several of these studies showed that cholinesterase inhibitors stabilized or slightly improved clinician impression of change as measured by CIBIC. However, the evidence of the effects of cholinesterase inhibitors on functional measures, such as instrumental activities of daily living, is mixed. In general, the studies have shown little or no effect of cholinesterase inhibitors on functional decline after 6 months of treatment, and a small, but statistically significant, difference from placebo after 12 months of treatment.<sup>29–33</sup>

### **Ginkgo biloba, selegiline, vitamin E, and estrogen.**

The evidence is weak that other drugs besides cholinesterase inhibitors have important benefits in Alzheimer’s disease. A meta-analysis that examined only the 4 highest quality RCTs found a small (approximately 3%) difference in cognitive scales between patients taking ginkgo biloba compared with placebo.<sup>34</sup> A recent Cochrane review and meta-analysis of 15 placebo-controlled studies found that using selegiline led to no clinically important differences from placebo.<sup>35</sup> A well-conducted 2-year RCT of the effect of vitamin E on moderate Alzheimer’s disease found no effect on cognition and limited evidence that it delayed institutionalization.<sup>36</sup> A well-conducted RCT examined estrogen therapy for women with mild to moderate dementia and found no evidence of clinical benefit.<sup>37</sup>

### **Pharmacotherapy for vascular dementia.**

Although antihypertensive treatment reduces the development of stroke and dementia, the evidence is limited that similar treatment of people with mild

to moderate dementia delays disease progression.<sup>38</sup> Recent studies have found no clinical benefit of nimodipine or aspirin in people with vascular dementia.<sup>38, 39</sup>

## Non-pharmacological Interventions

Several studies have examined non-pharmacological interventions (eg, behavioral training, caregiver education, and supportive services), directed at either the patient or the caregiver, in improving patient or caregiver outcomes. A systematic review and an RCT examined interventions directed at caregivers of people with mild to moderate dementia and found no significant differences in caregiver burden between intervention and control groups.<sup>40, 41</sup> Four well-conducted RCTs testing multi-component interventions yielded positive benefits. Two produced modest benefits in caregiver outcomes,<sup>42, 43</sup> and 2 studies found that intensive, comprehensive caregiver interventions enabled the caregivers to maintain affected persons at home for 11 to 19 months longer compared with those who did not receive the intervention.<sup>44, 45</sup> None of these studies demonstrated a significant impact on patient outcomes. Subjects in these studies had clinically diagnosed disease and needed caregivers. The extent to which such interventions would be useful to caregivers of people with milder degrees of dementia (as is likely to occur in those detected by screening) is unclear. Additionally, these studies used multi-component interventions, making it difficult to assess the impact of individual components. These factors make it difficult to generalize the potential benefits of these interventions to patients who would be detected by routine screening in primary care settings.

Early detection and treatment of dementia due to a reversible cause is a potential benefit of screening for dementia. The USPSTF reviewed evidence to assess the prevalence of dementias due to conditions such as vitamin B12 deficiency, thyroid disease, neurosyphilis, normal pressure hydrocephalus, or sleep apnea. No study provided information applicable to a screened population; the data from studies done in specialty clinics indicate that only 1.5% of cases could be classified as fully reversible dementia.<sup>3</sup>

## Potential Adverse Effects of Screening

The harms of dementia screening have not been systematically examined. Both false-positive and true-positive results could have adverse psychological effects on patients, but the USPSTF found few studies that address these outcomes. In one study of patients undergoing a detailed assessment of mental function, fewer than 5% found the screening itself distressing, intrusive, or depressing<sup>46</sup>; no studies were found of patient attitudes toward more limited tests of cognitive function such as the MMSE. Once screening identifies an individual with low cognitive function, clinicians have some concern over the disclosure of information to patients regarding their dementia status. The USPSTF found several case reports of suicide in patients with newly diagnosed Alzheimer's disease,<sup>47, 48</sup> but found no evidence of this potential adverse event in screening studies. A diagnosis of dementia could have effects on a patient's autonomy, but the USPSTF found no evidence supporting this concern. More established risks of receiving the diagnosis of dementia are difficulty obtaining medical or life insurance, or acceptance into assisted-living communities.

The most commonly reported adverse effects in patients taking cholinesterase inhibitors are nausea, vomiting, weight loss, and diarrhea. Tacrine also has significant gastrointestinal and hepatic adverse effects. The dropout rates in RCTs of cholinesterase inhibitors were higher in the groups taking cholinesterase inhibitors than in those taking placebo. In RCTs of other drugs, dropout rates did not differ significantly between those who took ginkgo biloba, selegiline, or vitamin E and those who took placebos.

## Recommendations of Others

There are no formal recommendations for routine screening for dementia. The American Academy of Neurology and the Canadian Task Force on Preventive Health Care concluded that there is insufficient evidence to recommend cognitive screening of asymptomatic individuals.<sup>49, 50</sup> The American Medical Association and the American Academy of Family Physicians recommend that physicians be alert for cognitive and functional decline in elderly patients for recognition of dementia in its early stages.<sup>51, 52</sup>

## References

1. U.S. Preventive Services Task Force. *Guide to Clinical Preventive Services*. 2nd ed. Washington, DC: Office of Disease Prevention and Health Promotion; 1996.
2. Boustani M, Peterson B, Hanson L, Harris R, Lohr K. Screening for dementia in primary care: a summary of the evidence for the U.S. preventive services task force. *Ann Int Med*. 2003;138:927–937.
3. Boustani M, Peterson B, Harris R, et al. *Screening for Dementia*. Systematic Evidence Review. Agency for Healthcare Research and Quality. Rockville, MD (in press).
4. American Psychiatric Association, ed. *Diagnostic and Statistical Manual of Mental Disorders*. 4th ed. Washington DC; 1994.
5. Morris J, Storandt M, Miller J, et al. Mild cognitive impairment represents early-stage Alzheimer disease. *Arch Neurol*. 2001;58(3):397–405.
6. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. *Am J Public Health*. 1994;84(8):1261–1264.
7. Lautenschlager N, Cupples L, Rao V, et al. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old? *Neurology*. 1996;46(3):641–650.
8. Blacker D, Tanzi R. The genetics of Alzheimer disease: current status and future prospects. *Arch Neurol*. 1998;55(3):294–296.
9. Lai F, Williams R. A prospective study of Alzheimer disease in Down syndrome. *Arch Neurol*. 1989;46(8):849–853.
10. Longstreth WJ, Bernick C, Manolio T, Bryan N, Jungreis C, Price T. Lacunar infarcts defined by magnetic resonance imaging of 3,660 elderly people: the Cardiovascular Health Study. *Arch Neurol*. 1998;55(9):1217–1225.
11. Hofman A, Ott A, Breteler M, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. *Lancet*. 1997;349(9046):151–154.
12. Costa PT Jr, Williams T, Somerfield M, et al. Early identification of Alzheimer's disease and related dementias. *Clinical Practice Guideline, Quick Reference Guide for Clinicians, No. 19*. Vol. AHCPR Publication No. 97-0703. Rockville, MD; 1996:1–28.
13. Wilder D, Cross P, Chen J, et al. Operating characteristics of brief screens for dementia in a multicultural population. *Am J Geriatric Psychiatry*. 1995;3(2):96–107.
14. Jitapunkul S, Lailert C, Worakul P, et al. Chula Mental Test: A screening test for elderly people in less developed countries. *Int J Geriatr Psychiatry*. 1996;11(8):714–720.
15. McDowell I, Kristjansson B, Hill GB, Hebert R. Community screening for dementia: the Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. *J Clin Epidemiol*. 1997;50(4):377–383.
16. Lindeboom J, Launer LJ, Schmand BA, Hooyer C, Jonker C. Effects of adjustment on the case-finding potential of cognitive tests. *J Clin Epidemiol*. 1996;49(6):691–695.
17. Law S, Wolfson C. Validation of a French version of an informant-based questionnaire as a screening test for Alzheimer's disease. *Br J Psychiatry*. 1995;167(4):541–544.
18. Braekhus A, Laake K, Engedal K. A low, 'normal' score on the Mini-Mental State Examination predicts development of dementia after three years. *J Am Geriatr Soc*. 1995;43(6):656–661.
19. Heun R, Papassotiropoulos A, Jennssen F. The validity of psychometric instruments for detection of dementia in the elderly general population. *Int J Geriatr Psychiatry*. 1998;13(6):368–380.
20. Birks J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease (Cochrane Review). *Cochrane Database Syst Rev*. 2000(2):CD001191.
21. Birks J, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease (Cochrane Review). *Cochrane Database Syst Rev*. 2000(4):CD001190.
22. Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. *JAMA*. 1998;280(20):1777–1782.
23. Olin J, Schneider L. Galantamine for Alzheimer's disease. *Cochrane Database Syst Rev*. 2002;3:CD001747.
24. Greenberg S, Tennis M, Brown L, et al. Donepezil therapy in clinical practice: a randomized crossover study. *Arch Neurol*. 2000;57(1):94–99.

25. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease – results from a multinational trial. *Dement Geriatr Cogn Disord*. 1999;10(3):237–244.
26. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. *BMJ*. 1999;318(7184):633–638.
27. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. *Neurology*. 2001;57(3):481–488.
28. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. *Neurology*. 2001;57(3):489–495.
29. Petracca G, Teson A, Chemerinski E, Leiguarda R, Starkstein S. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. *J Neuropsychiatry Clin Neurosci*. 1996;8(3):270–275.
30. Auchus A, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. *J Neuropsychiatry Clin Neurosci*. 1997;9(4):591–593.
31. Devanand D, Marder K, Michaels K, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. *Am J Psychiatry*. 1998;155(11):1512–1520.
32. Lyketsos CG, Sheppard JM, Steele CD, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. *Am J Psychiatry*. 2000;157(10):1686–1689.
33. Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. *Neurology*. 2000;55(9):1271–1278.
34. Oken B, Storzbach D, Kaye J. The efficacy of ginkgo biloba on cognitive function in Alzheimer disease. *Arch Neurol*. 1998;55(11):1409–1415.
35. Birks J, Flicker L. Selegiline for Alzheimer's disease (Cochrane Review). *Cochrane Database Syst Rev*. 2000(2):CD000442.
36. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. *N Engl J Med*. 1997;336(17):1216–1222.
37. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. *JAMA*. 2000;283(8):1007–1015.
38. Pantoni L, Rossi R, Inzitari D, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. *J Neurol Sci*. 2000;175(2):124–134.
39. Williams B, Rands G, Orrel M, Spector A. Aspirin for vascular dementia. *Cochrane Database Syst Rev*. 2000(4):CD001296.
40. Thompson C, Briggs M. Support for carers of people with Alzheimer's type dementia (Cochrane Review). *Cochrane Database Syst Rev*. 2000(3):CD000454.
41. Tappen RM. The effect of skill training on functional abilities of nursing home residents with dementia. *Res Nurs Health*. 1994;17(3):159–165.
42. McCurry SM, Logsdon RG, Vitiello MV, Teri L. Successful behavioral treatment for reported sleep problems in elderly caregivers of dementia patients: a controlled study. *J Gerontol B Psychol Sci Soc Sci*. 1998;53(2):122–P1299.
43. Marriott A, Donaldson C, Tarrier N, Burns A. Effectiveness of cognitive-behavioural family intervention in reducing the burden of care in carers of patients with Alzheimer's disease. *Br J Psychiatry*. 2000;176:557–562.
44. Mittelman MS, Ferris SH, Steinberg G, et al. An intervention that delays institutionalization of Alzheimer's disease patients: treatment of spouse-caregivers. *Gerontologist*. 1993;33(6):730–740.
45. Brodaty H, Gresham M, Luscombe G. The Prince Henry Hospital dementia caregivers' training programme. *Int J Geriatr Psychiatry*. 1997;12(2):183–192.
46. Jorm A, Henderson A, Scott R, Mackinnon A, Korten A, Christensen H. Do mental health surveys disturb? Further evidence. *Psychol Med*. 1994;24(1):233–237.

47. Conwell Y, Caine E. Rational suicide and the right to die. Reality and myth. *N Engl J Med.* 1991;325(15):1100–1103.
48. Rohde K, Peskind E, Raskind M. Suicide in two patients with Alzheimer's disease. *J Am Geriatr Soc.* 1995;43(2):187–189.
49. Anonymous. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. *Neurology.* 2001;56:1133–1142.
50. Canadian Task Force on the Periodic Health Examination. *Canadian guide to clinical prevention health care.* Ottawa: Canada Communication Group; 1994:902–909.
51. American Medical Association. Practical guide for the Primary Care Physician on the Diagnosis, Management and Treatment of Dementia. *Program on Aging and Community Health.* Chicago, IL, 2001. Available at: <http://www.ama-assn.org/ama/pub/category/4789.html>. Accessed Jan 10, 2003.
52. Santacruz KS, Swagerty D. Early diagnosis of dementia, *American Family Physician,* 2001. Available at: <http://www.aafp.org/afp/monograph/>. Accessed Jan 10, 2003.

## Appendix A U.S. Preventive Services Task Force – Recommendations and Ratings

The Task Force grades its recommendations according to one of 5 classifications (A, B, C, D, I) reflecting the strength of evidence and magnitude of net benefit (benefits minus harms):

- A.** The USPSTF strongly recommends that clinicians routinely provide [the service] to eligible patients. *The USPSTF found good evidence that [the service] improves important health outcomes and concludes that benefits substantially outweigh harms.*
- B.** The USPSTF recommends that clinicians routinely provide [the service] to eligible patients. *The USPSTF found at least fair evidence that [the service] improves important health outcomes and concludes that benefits outweigh harms.*
- C.** The USPSTF makes no recommendation for or against routine provision of [the service]. *The USPSTF found at least fair evidence that [the service] can improve health outcomes but concludes that the balance of benefits and harms is too close to justify a general recommendation.*
- D.** The USPSTF recommends against routinely providing [the service] to asymptomatic patients. *The USPSTF found at least fair evidence that [the service] is ineffective or that harms outweigh benefits.*
- I.** The USPSTF concludes that the evidence is insufficient to recommend for or against routinely providing [the service]. *Evidence that [the service] is effective is lacking, of poor quality, or conflicting and the balance of benefits and harms cannot be determined.*

## Appendix B U.S. Preventive Services Task Force – Strength of Overall Evidence

The USPSTF grades the quality of the overall evidence for a service on a 3-point scale (good, fair, poor):

- Good:** Evidence includes consistent results from well-designed, well-conducted studies in representative populations that directly assess effects on health outcomes.
- Fair:** Evidence is sufficient to determine effects on health outcomes, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence on health outcomes.
- Poor:** Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information on important health outcomes.

### Members of the U.S. Preventive Services Task Force

**Alfred O. Berg, MD, MPH, Chair, USPSTF** (Professor and Chair, Department of Family Medicine, University of Washington, Seattle, WA)

**Janet D. Allan, PhD, RN, Vice-chair, USPSTF** (Dean, School of Nursing, University of Maryland Baltimore, Baltimore, MD)

**Paul Frame, MD** (Tri-County Family Medicine, Cohocton, NY, and Clinical Professor of Family Medicine, University of Rochester, Rochester, NY)

**Charles J. Homer, MD, MPH\*** (Executive Director, National Initiative for Children's Healthcare Quality, Boston, MA)

**Mark S. Johnson, MD, MPH** (Chair, Department of Family Medicine, University of Medicine and Dentistry of New Jersey—New Jersey Medical School, Newark, NJ)

**Jonathan D. Klein, MD, MPH** (Associate Professor, Department of Pediatrics, University of Rochester School of Medicine, Rochester, NY)

**Tracy A. Lieu, MD, MPH\*** (Associate Professor, Department of Ambulatory Care and Prevention, Harvard Medical School, Boston, MA)

**Cynthia D. Mulrow, MD, MSc\*** (Clinical Professor and Director, Department of Medicine, University of Texas Health Science Center, San Antonio, TX)

**C. Tracy Orleans, PhD** (Senior Scientist and Senior Program Officer, The Robert Wood Johnson Foundation, Princeton, NJ)

**Jeffrey F. Peipert, MD, MPH\*** (Director of Research, Women and Infants' Hospital, Providence, RI)

**Nola J. Pender, PhD, RN\*** (Professor Emeritus, University of Michigan, Ann Arbor, MI)

**Albert L. Siu, MD, MSPH** (Professor of Medicine, Chief of Division of General Internal Medicine, Mount Sinai School of Medicine, New York, NY)

**Steven M. Teutsch, MD, MPH** (Senior Director, Outcomes Research and Management, Merck & Company, Inc., West Point, PA)

**Carolyn Westhoff, MD, MSc** (Professor of Obstetrics and Gynecology and Professor of Public Health, Columbia University, New York, NY)

**Steven H. Woolf, MD, MPH** (Professor, Department of Family Practice and Department of Preventive and Community Medicine, Fairfax, VA)

\*Member of the USPSTF at the time this recommendation was finalized.